Merck & Co., Inc.
Undisclosed program
Resolved
68days ago
Phase 3 readout · Apr 30, 2026
What's at stake
Phase 3 trial results for Undisclosed program in its lead indication are due Apr 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Presented New Data From Cardio-Pulmonary Pipeline at ACC.26, Including Positive Results From Phase 3 CORALreef AddOn Trial”